OBJECTIVE: To compare the effectiveness and safety of Betahistine dihydrochloride (in beta cyclodextrin) with Betahistine dihydrochloride in treating patients with vertigo.
DESIGN/METHODS: This was a randomized, open label study enrolling 68 patients, ages 18 to 65 years old, diagnosed clinically with vertigo.
RESULTS: Sixty two patients completed the study. EEV scores of both groups continuously decreased to similar levels. EEV scores significantly deceased from baseline to week 4. In group A patients, EEV scores decreased from 9.81+/- 3.73 at baseline to 2.39 +/- 3.46, p<.001; similarly, in group B patients, EEV scores fell from 12.32 +/- 3.61 to 2.32 +/- 2.32 +/- .48, p
Group A patients reported 2.6 +\- 2.9 side effects while Group B patients reported 2.7 +/- 2.5 side effects (p=0.92). There were more patients who experienced vomiting, abdominal pain, nausea, vomiting and/ or diarrhea in Group B patients (8/32 in Group A vs 16/30 in Group B, p=0.022).
CONCLUSION: Betahistine dihydrochloride with beta cyclodextrin and Betahistine dihydrochloride alone are both effective in reducing the symptoms of dizziness from vertiginous syndromes. Betahistine dihydrochloride with beta cyclodextrin appears to have less gastrointestinal side effects than Betahistine dihydrochloride alone.

Human ; Male ; Female ; Aged ; Middle Aged ; Adult ; Young Adult ; Vertigo ; Safety ; Betahistine ; Dizziness ; Nausea ; Syndrome ; Vertigo ; Vomiting ; Beta-cyclodextrins

Objective: To determine the prevalence of hearing loss and otologic diseases among Filipinos living in the Southern Tagalog Region IV-A: CALABARZON (Cavite, Laguna, Batangas, Rizal and Quezon), Philippines.

Methods:

               Design: Retrospective Review of Community Survey Data

               Setting: Communities in Region IV-A provinces, Philippines

               Participants: 3267 residents of the five provinces aged 0 months and above

 Results: About 71.29% and 74.60% had at least mild hearing loss, in right and left ears, respectively. For disabling hearing impairment, overall prevalence was 26.33%, distributed into 11.87% among 4 to 18-year-olds; 8.97% for 19 to 64-year-olds; and 3.17% for 65-year-olds and above. Absence of prevalent and hearing loss-associated diseases: serous otitis media [OR 0.362, 95% CI 0.167 to 0.782, p = .010], CSOM [OR 0.407, 95% CI 0.236 to 0.703, p = .001] COM [OR 0.229, 95% CI 0.106 to 0.494, p < .001] can decrease the risk for hearing loss development in the region. Prevention of noise-induced hearing loss or delay in the manifestation of presbycusis can reduce the risk of having hearing loss by as much as 75% [OR 0.253, 95% CI (0.180 to 0.355), p < .001]. All pure tone audiometry measurements were obtained with surrounding median ambient noise of 55dB (IQR 46 to 60dB).

Conclusion: The prevalence of hearing loss among surveyed residents of the Southern Tagalog Region IV-A provinces was high compared to the previous nationwide study but low compared to other low- and middle-income countries. The top otologic conditions of this population (ear occlusion with ear wax, chronic suppurative otitis media, chronic otitis media, presbycusis, noise-induced hearing loss) were associated with hearing loss and their absence decreased the risks for hearing impairment.

Human ; Male ; Female ; Aged (a Person 65 Through 79 Years Of Age) ; Middle Aged (a Person 45-64 Years Of Age) ; Prevalence ; Hearing Loss ; Pediatrics ; Adult ; Presbycusis ; Otoscopy ; Otolaryngology